Journal
FRONTIERS IN PHARMACOLOGY
Volume 11, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2020.01240
Keywords
rimegepant; gepant; antagonist; calcitonin gene-related peptide; amylin; migraine; AMY(1)
Categories
Funding
- Auckland Medical Research Foundation
- Kelliher Charitable Trust
- James Cook Research Fellowship from the Royal Society of New Zealand
- Health Research Council, New Zealand
- University of Auckland
Ask authors/readers for more resources
The gepants are a class of calcitonin gene-related peptide (CGRP) receptor antagonist molecules that have been developed for the prevention and treatment of migraine. Rimegepant is reported to act at the CGRP receptor, has good oral bioavailability, and has had positive clinical trial results. However, there is very little data available describing its receptor pharmacology. Importantly, rimegepant activity at the AMY(1)receptor, a second potent CGRP receptor that is known to be expressed in the trigeminovascular system, has not been reported. The ability of rimegepant to antagonize activation of human CGRP, AMY(1), and related adrenomedullin receptors was determined in transfected in Cos7 cells. Rimegepant was an effective antagonist at both the CGRP and AMY(1)receptor. The antagonism of both CGRP and AMY(1)receptors may have implications for our understanding of the mechanism of action of rimegepant in the treatment of migraine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available